Northern Biomolecular Services (NBS) is a contract research organization in Kalamazoo Michigan, specializing in advanced molecular biological techniques for the determination of biodistribution, persistence, and gene expression of cell and gene therapy products in biological samples through real-time qPCR quantification analysis. NBS provides a complete solution for customized assay development, robust validation procedures, and efficient sample processing workflows. Delivering high-quality data and providing customer satisfaction is the top priority.
With premier GLP CRO industry experience, the staff at NBS has effectively managed to develop skill and expertise in RNA and DNA extraction techniques utilizing kits as well as automated high throughput instruments for sample processing. Method development and optimization is included in the assay design in order to develop a complete, validated, robust assay with real time qPCR sensitivity that far outweighs industry expectations. Utilizing well known and highly respected industry partners to implement cutting edge instrumentation, the lab is capable of providing a superior overall experience from proposal initiation through data reporting and study finalization.
Shane Woods is the co-founder and President of NBS, bringing over 18 years of experience in development and evaluation of gene therapies, regenerative medicines and medical devices. Prior to NBS Shane served as a Senior Study Director and Director for MPI Research/Charles River Laboratories overseeing Surgical Operations and the Cell and Molecular Biology laboratory. Before Joining Charles River Shane worked as a scientist for Depuy Synthes Bio-materials and ETEX Corporation developing and testing novel materials for orthopedic applications. Shane Holds an MBA and a MS in Mechanical Engineering from Colorado state and has a BS in Cell and Molecular Biology.
Scientific leader with over 30 years of experience in academic laboratories, pharmaceutical industry, and contracted research, and with a broad background in molecular and cell biology, applications of cell and gene therapy, bioanalysis of DNA/RNA/proteins, and virology. Led the establishment of a GLP compliant molecular biology lab, acting as a scientific lead in preclinical biodistribution, vector shedding, vector-derived gene expression, and formulation analysis of gene and therapy products in animals and clinical vector shedding and PK of CAR-T cells for over 11 years. Served as a Study Director or a Contributing Scientist in 150+ studies where primary responsibilities included overall planning and conduct of qPCR and RT-qPCR method development, qualification/validation, and sample analysis to support preclinical and clinical development of gene and cell therapy products, in accordance with regulatory guidelines and contemporary scientific practice.
Cell and molecular biologist with over 10 years of experience in GLP-compliant industry and academic environments. Within the GLP setting she served as lead scientist responsible for the method development and validation for the biodistribution of cell and viral vector test articles, relative and absolute gene expression, and viral vector formulation analysis. She has also served as a study director in charge of planning and overseeing the execution of similar studies for both preclinical and clinical work, as well as developing study plans for the analysis of RNA silencing vectors. She has presented work at the American Society of Gene and Cell Therapy on the development of robust assays necessary for consistent and quality data. Kristin earned her PhD at the University of Cincinnati researching the role of transcription factor regulation of intestinal stem cell homeostasis in embryonic and adult mice at both Cincinnati Children’s Hospital and Baylor College of Medicine.
Technically skilled and results-driven scientist with over ten years of experience in multiple levels of preclinical research. Recognized for excellent lab skills in molecular biology techniques, displaying a strong understanding of the necessity for operational efficiencies and high quality research. Rossi brings knowledge of the preclinical environment serving in previous roles with hands on animal laboratory experience and surgical based settings as an AALAC Certified Laboratory Animal Technologist, as well as serving in roles requiring data interpretation and report coordination following regulatory requirements. She graduated from Kalamazoo College in 2009 with a Bachelor of Arts in Biology. During her time there, she studied abroad in Perth, Australia and performed research on Human Xenograft Tumor Models in Nude Mice for the evaluation of various cancer therapies.
Mark Johnson is the board member and co-founder of NBS, with over 25 years' experience in the development and evaluation of gene therapies, regenerative medicines and medical devices. Prior to founding NBS, Mark served as a Senior Study Director and Senior Director of Surgery, Ophthalmology and Cell and Molecular Biology for Charles River Laboratories. In his role with Charles River/ MPI Research, Mark was responsible for the overall management of his business line. During his tenure, he was responsible for the conduct of several hundred GLP and Non-GLP studies in support of IND's, NDA's, IDE's and PMA's. Mark holds a Master's Degree in Neuroscience.